Forte Biosciences reports Q1 EPS (16c), two estimates (16c)

“Forte continues to make excellent progress with FB102. As we indicated last quarter, the single ascending dose (SAD) portion of the FB102 phase 1 trial was successfully completed. We expect the dosing of the multiple ascending dose (MAD) cohorts of the phase 1 trial in the healthy volunteers to complete around mid-year. To date, FB102 has demonstrated a good safety profile, including in the MAD cohorts,” said Paul Wagner, Ph.D., Chairman and Chief Executive Officer of Forte Biosciences. “We look forward to initiating patient-based studies before the end of the year. We believe the data to date supports the significant potential for FB102 across a variety of autoimmune and autoimmune-related diseases with large addressable markets and we look forward to addressing these opportunities as we continue to advance the FB102 program.”